• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Allurion Technologies Inc.

    11/17/25 4:08:14 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care
    Get the next $ALUR alert in real time by email
    NT 10-Q 1 alur_q3_nt10-q.htm NT 10-Q NT 10-Q

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 12b-25

    NOTIFICATION OF LATE FILING

     

     

     

     

    (Check One):

    ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q

    ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

     

     

     

    For Period Ended: September 30, 2025

     

     

     

    ☐ Transition Report on Form 10-K

     

    ☐ Transition Report on Form 20-F

     

    ☐ Transition Report on Form 11-K

     

    ☐ Transition Report on Form 10-Q

     

     

     

    For the Transition Period Ended: N/A

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A

    PART I — REGISTRANT INFORMATION

    ALLURION TECHNOLOGIES, INC.

    (Full Name of Registrant)

     

    Not Applicable

    (Former Name if Applicable)

     

    11 Huron Drive

    (Address of Principal Executive Office (Street and Number))

     

    Natick, Massachusetts 01760

    (City, State and Zip Code)

     

    PART II — RULES 12b-25(b) AND (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     


     

     

     

     

     

     

     

    x

     

     

    x

     

     

     

     

    ¨

     

     

    (a)

    The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

    (b)

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

    (c)

    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached, if applicable.

    PART III — NARRATIVE

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

    Allurion Technologies, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the “Form 10-Q”) by the November 14, 2025 filing date applicable to a non-accelerated filer for the reasons discussed in this Form 12b-25.

    The Company needed additional time beyond the original filing deadline for the Form 10-Q to complete its preparation and review of items that occurred subsequent to quarter end. As of the date of this notification of late filing, such preparation and review have been completed. The Company expects to file the Form 10-Q on the date hereof, which is within the five-day extension period provided by filing this notification.

     

     


     

    PART IV — OTHER INFORMATION

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    (1)

    Name and telephone number of person to contact in regard to this notification

     

     

     

     

     

     

     

     

     

    Brendan M. Gibbons

     

     

     

    (508)

     

     

     

    647-4000

     

     

    (Name)

     

    (Area Code)

     

    (Telephone Number)

     

     

     

    (2)

     

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

    ☒ Yes ☐ No

     

     

     

    (3)

     

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

     

    ☒ Yes ☐ No

     

     

     

     

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    The Company expects to report: total revenue of approximately $2.7 million for the three months ended September 30, 2025, compared to approximately $5.4 million for the three months ended September 30, 2024; gross profit of approximately $1.3 million for the three months ended September 30, 2025 compared to approximately $3.1 million for the three months ended September 30, 2024; sales and marketing expenses of approximately $3.1 million for the three months ended September 30, 2025 compared to approximately $5.2 million for the three months ended September 30, 2024; research and development expenses of approximately $2.0 million for the three months ended September 30, 2025 compared to approximately $3.2 million for the three months ended September 30, 2024; general and administrative expenses of approximately $5.8 million for the three months ended September 30, 2025 compared to approximately $7.0 million for the three months ended September 30, 2024; and loss from operations of approximately $9.6 million for the three months ended September 30, 2025 compared to approximately $12.3 million for the three months ended September 30, 2024.

     

    Cautionary Note on Forward-Looking Statements

     

    This Form 12b-25 includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. All statements, other than statements of historical fact, included in this Form 12b-25 are forward-looking statements, including statements regarding the Company’s expectations regarding the timing of the filing with the SEC of the Form 10-Q. Such forward looking statements may be identified by, among other things, the use of forward-looking terminology such as “believe,” “expect,” “may,” “could,” “would,” “plan,” “intend,” “estimate,” “predict,” “potential,” “continue,” “should” or “anticipate” or the negative thereof or other variations thereon or comparable terminology.

     

    Forward-looking statements are based on beliefs and assumptions by management and the Board of Directors of the Company (the “Board”), and on information currently available to the Board and management. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential consequences of the matters discussed in this Form 12b-25 include, but are not limited to: the risk that the completion and filing of the Form 10-Q will take longer than expected and will not be completed by the extension period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended; the possibility that the New York Stock Exchange may delist the Company’s securities; the possibility that the Company will become delinquent in its filings with the SEC; the risk of investigations or actions by governmental authorities or regulators and the consequences thereof, including the imposition of civil or criminal penalties; and the risk that the Company may become subject to stockholder lawsuits or claims. It is very difficult to predict the effect of known factors, and the Company cannot anticipate all factors that could affect actual results that may be important to an investor. All

     


     

    forward-looking information should be evaluated in the context of these risks, uncertainties and other factors, including those factors disclosed under “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the SEC on March 27, 2025, as amended, and the Company’s subsequent reports filed with the SEC.

     

    All forward-looking statements in this Form 12b-25 are based on information available to the Company as of the date hereof. The Company undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

     

     


     

    ALLURION TECHNOLOGIES, INC.

    (Name of Registrant as Specified in Charter)

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

     

     

     

     

     

    Date: November 17, 2025

     

    By:

    /s/ Brendan M. Gibbons

     

     

     

    Name:

    Brendan M. Gibbons

     

     

     

    Title:

    Chief Legal Officer

     

     

     

     


    Get the next $ALUR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALUR

    DatePrice TargetRatingAnalyst
    11/14/2024Buy → Neutral
    Chardan Capital Markets
    10/2/2024$2.00Buy
    TD Cowen
    9/6/2024$2.00Buy
    ROTH MKM
    2/9/2024$5.00Buy
    Jefferies
    More analyst ratings

    $ALUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Allurion Technologies downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

    11/14/24 8:29:33 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Allurion Technologies with a new price target

    TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

    10/2/24 7:13:57 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    ROTH MKM initiated coverage on Allurion Technologies with a new price target

    ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

    9/6/24 7:25:38 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rtw Investments, Lp was granted 1,856,288 shares (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    11/13/25 5:26:01 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Director Rtw Investments, Lp converted options into 1,492,539 shares (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    11/7/25 5:18:07 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    5/21/25 4:15:08 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

    Case-controlled study in 1,143 patients demonstrates superior weight reduction, fat mass loss, and visceral fat loss with the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone Average weight reduction of 20% at 36 weeks, on par with bariatric surgery and high-dose GLP-1 therapy Improved body composition without adversely affecting muscle mass Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of a peer-reviewed, case-controlled study on the use of the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone and its impact

    11/20/25 9:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

    Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with ProSurg Medical, a leading Brazilian medical device company specializing in bariatric and obesity care. This new partnership draws upon ProSurg Medical's 30-year experience in the Brazilian market and reflects Allurion's commitment to establishing a new standard of care in obesity management focused on metabolically healthy weight loss. ProSurg Medical has extensive experience in building high-performing medical networks spanning over 300 hospitals across Brazil with teams that include dietitians, bariatric surgeons, and endoscopic specialists

    11/18/25 9:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update. Recent Company Highlights Successfully passed U.S. Food and Drug Administration ("FDA") Pre-Approval Inspection and Bioresearch Monitoring (BIMO) audit with zero observations and no Form 483 issued Completed Premarket Approval ("PMA") Acceptance and Filing Reviews, entered Substantive Review for the Allurion Smart Capsule and successfully completed Day-100 meeting Entered into transaction to exchange all outstanding debt for convertible preferred equity and concurrently announced private placement fina

    11/12/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    SEC Filings

    View All

    SEC Form 424B3 filed by Allurion Technologies Inc.

    424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    11/18/25 4:08:29 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Allurion Technologies Inc.

    424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    11/18/25 4:06:03 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Allurion Technologies Inc.

    10-Q - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    11/17/25 4:14:00 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    5/21/25 4:15:08 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    4/1/25 4:15:07 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Leadership Updates

    Live Leadership Updates

    View All

    Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

    Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

    9/3/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

    Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

    8/20/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

    Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

    6/5/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Financials

    Live finance-specific insights

    View All

    Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update. Recent Company Highlights Successfully passed U.S. Food and Drug Administration ("FDA") Pre-Approval Inspection and Bioresearch Monitoring (BIMO) audit with zero observations and no Form 483 issued Completed Premarket Approval ("PMA") Acceptance and Filing Reviews, entered Substantive Review for the Allurion Smart Capsule and successfully completed Day-100 meeting Entered into transaction to exchange all outstanding debt for convertible preferred equity and concurrently announced private placement fina

    11/12/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

    Passing of key audits with zero findings and completion of Day-100 meeting are significant milestones in the FDA PMA process as the Company enters final stages of FDA review process for its Allurion Smart Capsule Exchange of outstanding debt for shares of convertible preferred stock would result in Company being debt-free $5M private placement financing with participation from new and existing stockholders and a strategic partner with deep obesity expertise significantly strengthens Company's financial position as the Company seeks FDA approval Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced it has

    11/11/25 8:45:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025

    Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the third quarter 2025 on Wednesday, November 12, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay

    11/6/25 4:05:00 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:43:43 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:15:52 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Allurion Technologies Inc.

    SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    10/24/24 5:19:39 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care